MiMedx Group Q4 2022 Earnings Report

MiMedx Group EPS Results

• Actual EPS: -$0.02
• Consensus EPS: -$0.02
• Beat/Miss: Met Expectations
• One Year Ago EPS: N/A

MiMedx Group Revenue Results

• Actual Revenue: $74.38 million
• Expected Revenue: $74.31 million
• Beat/Miss: Beat by +$70.00 thousand
• YoY Revenue Growth: N/A

MiMedx Group Announcement Details

• Quarter: Q4 2022
• Date: 2/28/2023
• Time: N/A

MiMedx Group (NASDAQ:MDXG) develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins. The company's patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a barrier membrane allograft used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers; AmnioFix, a protective barrier allograft, which comprises dehydrated human amnion/chorion membrane for use in surgical recovery applications; and EpiCord and AmnioCord are dehydrated human umbilical cord allografts that are used to provide a protective environment for the healing process, as well as used in the advanced wound care and surgical recovery applications. The company's products have applications in the areas of wound care, burn, surgical sectors of healthcare. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. MiMedx Group, Inc. was founded in 2006 and is headquartered in Marietta, Georgia.